Doseology Sciences, Inc. (TSE:MOOD)

:MOOD

MOOD

Doseology Sciences

RESEARCH TOOLSreports

Want to see TSE:MOOD full AI Analyst Report?

Doseology Sciences (MOOD) Price & Analysis

6 Followers

MOOD Stock Chart & Stats

C$0.53

C$0.00(0.00%)

At close: Dec 31 4:00 PM EST

C$0.53

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.18 - C$1.90

Previous CloseN/A

Volume0.00

Average Volume (3M)1.79K

Market Cap

C$1.68M

Enterprise ValueC$1.23M

Total Cash (Recent Filing)C$1.43M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta-3.16

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding8,011,621

10 Day Avg. Volume3,383

30 Day Avg. Volume1,793

Financial Highlights & Ratios

PEG Ratio-0.49

Price to Book (P/B)3.46

Price to Sales (P/S)113.73

P/FCF Ratio-14.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-light Balance SheetA near-zero debt profile materially reduces solvency risk and interest burdens, giving management flexibility to fund R&D, product launches, or strategic partnerships without imminent covenant pressure. Over a 2–6 month horizon this strengthens the company's runway relative to leveraged peers.

Improving Cash BurnMaterial improvement in cash burn indicates progress toward tighter cost control and more disciplined cash management. If sustained, lower negative operating cash flow reduces near-term financing needs and extends runway, enabling focused execution on product commercialization.

Product And Partner Commercialization ModelA dual go-to-market approach—selling finished products and licensing ingredients/partners—provides diversified commercialization channels and scalability. This structural model can accelerate distribution, reduce per-product go-to-market cost, and hedge execution risk over multiple quarters.

Bears Say

Consistently Negative Cash FlowPersistent negative operating and free cash flow forces reliance on external capital (equity or debt), increasing dilution or financing costs. Over the medium term this constrains strategic investments, limits flexibility to scale products, and raises execution risk if capital markets tighten.

Small, Volatile Revenue And LossesA fragile and shrinking revenue base coupled with negative margins signals the business has not reached scalable unit economics. Revenue volatility undermines forecasting and hampers reinvestment returns, making sustainable growth and margin improvement uncertain over the next several quarters.

Eroding Shareholder ReturnsOngoing losses that produce negative ROE reduce book equity and can trigger dilution if management raises capital. This gradual erosion weakens the balance sheet buffer and increases risk that future financing needs will impose unfavorable terms or limit strategic options.

Doseology Sciences News

Doseology launches $2 million private placement to fund oral stimulant pouch rollout

Doseology Sciences ( ($TSE:MOOD) ) has issued an announcement. Doseology Sciences Inc. has arranged a non-brokered private placement...

2M ago

Doseology Uplists to OTCQB to Advance Growth in Oral Stimulant Pouch Market

An announcement from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has uplisted its common...

3M ago

Doseology debuts nicotine-free energy pouches in U.S. direct-to-consumer pilot

Doseology Sciences ( ($TSE:MOOD) ) has shared an announcement. Doseology Sciences has launched its Feed That Brain Energy...

3M ago

Doseology Taps Veteran Pharmacy Executive Larry Latowsky as Executive Chairman to Steer Commercial Expansion

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has appointed veteran retail and healthcare executive...

4M ago

Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has begun a pilot production run of...

5M ago

Doseology Boosts Transparency With New Annual Information Form Filing

Doseology Sciences ( ($TSE:MOOD) ) has issued an update. Doseology Sciences Inc. has filed its Annual Information Form...

5M ago

Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an announcement. Doseology Sciences has entered a strategic partnership with McKinney...

5M ago

Doseology Launches Investor Communications Initiative to Boost Market Engagement

The latest update is out from Doseology Sciences ( ($TSE:MOOD) ). Doseology Sciences Inc. has launched an Investor...

6M ago

Doseology Secures Strategic Manufacturing Agreement for Market Readiness

Doseology Sciences ( ($TSE:MOOD) ) has issued an announcement. Doseology Sciences Inc. has announced a significant milestone with...

7M ago

Doseology Sciences Expands Portfolio with Strategic Acquisition

An update from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has completed the acquisition...

10M ago

MOOD FAQ

What was Doseology Sciences, Inc.’s price range in the past 12 months?

Doseology Sciences, Inc. lowest stock price was C$0.18 and its highest was C$1.90 in the past 12 months.

What is Doseology Sciences, Inc.’s market cap?

Doseology Sciences, Inc.’s market cap is C$1.68M.

When is Doseology Sciences, Inc.’s upcoming earnings report date?

Doseology Sciences, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 143 days.

How were Doseology Sciences, Inc.’s earnings last quarter?

Doseology Sciences, Inc. released its earnings results on Jun 01, 2026. The company reported -C$0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.034.

Is Doseology Sciences, Inc. overvalued?

According to Wall Street analysts Doseology Sciences, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Doseology Sciences, Inc. pay dividends?

Doseology Sciences, Inc. does not currently pay dividends.

What is Doseology Sciences, Inc.’s EPS estimate?

Doseology Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Doseology Sciences, Inc. have?

Doseology Sciences, Inc. has 8,011,621 shares outstanding.

What happened to Doseology Sciences, Inc.’s price movement after its last earnings report?

Doseology Sciences, Inc. reported an EPS of -C$0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Doseology Sciences, Inc.?

Currently, no hedge funds are holding shares in TSE:MOOD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Doseology Sciences, Inc.

Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.